[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Seca\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":119},{"warningLetters":4,"total":118},[5,35,57,78,98],{"id":6,"raw":7,"subject":15,"body_html":16,"body_text":17,"firm_name":18,"letter_id":19,"created_at":20,"fei_number":21,"letter_url":22,"updated_at":23,"action_type":24,"case_status":25,"posted_date":26,"marcs_cms_no":27,"product_type":28,"closeout_date":29,"issuing_office":30,"recipient_name":31,"body_fetched_at":32,"delivery_method":33,"recipient_title":21,"reference_number":21,"action_taken_date":34,"medical_device_id":21,"response_letter_date":21},2100,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2023-05-16T13:20:00Z\">05\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-28T04:00:00Z\">04\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgarys-cheesecakes-fine-desserts-654471-04282023\">Gary’s Cheesecakes &amp; Fine Desserts\u003C\u002Fa>"," Division of Human and Animal Food Operations East V","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u003Cbr \u002F>\r\n","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgarys-cheesecakes-fine-desserts-654471-11082023\">\u003Ctime datetime=\"2023-11-17T05:00:00Z\">11\u002F17\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gary W. Haas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gary’s Cheesecakes &amp; Fine Desserts\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5285 Crookshank Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cincinnati\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45238-3364\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 654471\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 28, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Haas:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) bakery products manufacturing facility located at 5285 Crookshank Road, Cincinnati, Ohio 45238, on January 31 through February 15, 2023. During the inspection, the FDA investigator found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 Part CFR 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing deviations found at your facility.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the RTE bakery products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You can find the Act and FDA regulations through links in FDA's home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>FDA received your written response via email on March 7, 2023, describing the corrective actions you have taken and plan to take. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not take effective measures to exclude pests from your food manufacturing plant to protect against contamination of food, as required by 21 CFR § 117.35(c). Specifically, the following conditions were observed:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On January 31, 2023, an apparent dead rodent, attached to a glue trap inside of an open cardboard box, located next to the standing mixer.\u003C\u002Fli>\n\t\u003Cli>On January 31, 2023, approximately ten apparent rodent excreta pellets with a black, shiny, and soft appearance inside of a junction between preparation tables where RTE brownies were being iced.\u003C\u002Fli>\n\t\u003Cli>On January 31, 2023, apparent rodent excreta pellets with a black, shiny, and soft appearance, too numerous to count, between ingredient bags and directly below a storage rack used to store bulk dry ingredients.\u003C\u002Fli>\n\t\u003Cli>On January 31, 2023, apparent insect activity on a glue trap next to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> with an approximately one-inch gap.\u003C\u002Fli>\n\t\u003Cli>On February 8, 2023, multiple apparent dead insects attached to two glue traps, adjacent to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> oven. In addition, a section of the glue trap was torn, which you stated was due to a mouse that chewed through the glue trap to escape when it was caught on the trap.\u003C\u002Fli>\n\t\u003Cli>On February 13, 2023, apparent rodent excreta pellets with a black, dull, and hard appearance, too numerous to count, inside an enclosed shelf under the \u003Cstrong>(b)(4)\u003C\u002Fstrong> behind boxes containing icing piping bags and on a sheet pan used to store RTE brownies prior to slicing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This is a repeat observation from FDA’s 2020 inspection, as apparent rodent excrement was observed on and around an in-use caramel container used as a topping on RTE desserts, and on a shelf directly below where plates for the slicing machine are stored.\u003C\u002Fp>\n\n\u003Cp>Your March 7, 2023 response stated that you disposed of glue traps with captured pests, placed new glue traps, removed rodent excreta pellets, cleaned and sanitized areas where rodent excreta pellets were found, added cleaning tasks to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization schedule, and will schedule garage door maintenance. However, your response does not show that the corrective actions are being implemented on a continual basis, and that they are effectively excluding pests from your facility. Additionally, you did not provide evidence of the scheduled garage maintenance, such as a maintenance request or work order.\u003C\u002Fp>\n\n\u003Cp>We note that your most recent response includes corrective actions that you previously submitted to FDA on March 8, 2020, in response to FDA’s 2020 inspectional findings. As corrective action to the rodent excrement, your 2020 response stated that you cleaned and sanitized areas exposed to rodent excrement and placed new glue traps. However, during FDA’s most recent inspection, the investigators observed similar conditions, demonstrating that your corrective actions were inadequate and pest activity continues to persist in your facility. Additionally, during the most recent inspection, the FDA investigator discussed with you using a professional pest control service, you stated that you would contact a professional pest control company to inquire about servicing your facility; however, your response did not mention acquiring professional pest control services.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Register Food Facility:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, FDA has determined that your facility at 5285 Crookshank Road, Cincinnati, Ohio 45238 is subject to the food facility registration requirement in section 415 of the Act [21 U.S.C. § 350d], and our implementing regulation at 21 CFR Part 1, Subpart H. Section § 415(a)(3) of the Act requires facilities that are required to register with FDA to renew their registrations every other year during the period beginning on October 1 and ending on December 31 of each even-numbered year. \u003Cstrong>(b)(3)\u003C\u002Fstrong>. Failure to register a facility as required is a prohibited act under section 301(dd) of the Act [21 U.S.C. § 331(dd)].\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We request that the owner, operator, or agent in charge of this facility, or an individual authorized by this facility’s owner, operator, or agent in charge, register the facility with FDA within 30 working days of date of this letter. Food facility registration guidance is available online at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions\u003C\u002Fa>. Registration may be accomplished online at \u003Ca href=\"http:\u002F\u002Fwww.access.fda.gov\u002F\">http:\u002F\u002Fwww.access.fda.gov\u003C\u002Fa>. You must submit your registration or registration renewal to FDA electronically, unless FDA has granted you a waiver under 21 CFR 1.245 (21 CFR 1.231(a)(4)).\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may also reach Christopher Dedeaux at 504-846-6122 or if you have any questions regarding this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nGary W. Haas\n\nRecipient Title\n\nOwner\n\nGary’s Cheesecakes & Fine Desserts\n\n5285 Crookshank Road\n\nCincinnati, OH 45238-3364\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nWARNING LETTER 654471\n\nApril 28, 2023\n\nDear Mr. Haas:\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) bakery products manufacturing facility located at 5285 Crookshank Road, Cincinnati, Ohio 45238, on January 31 through February 15, 2023. During the inspection, the FDA investigator found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 Part CFR 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing deviations found at your facility.\n\nBased on FDA’s inspectional findings, we have determined that the RTE bakery products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You can find the Act and FDA regulations through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nFDA received your written response via email on March 7, 2023, describing the corrective actions you have taken and plan to take. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\n\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B):\n\nYou did not take effective measures to exclude pests from your food manufacturing plant to protect against contamination of food, as required by 21 CFR § 117.35(c). Specifically, the following conditions were observed:\n\nOn January 31, 2023, an apparent dead rodent, attached to a glue trap inside of an open cardboard box, located next to the standing mixer.\n\nOn January 31, 2023, approximately ten apparent rodent excreta pellets with a black, shiny, and soft appearance inside of a junction between preparation tables where RTE brownies were being iced.\n\nOn January 31, 2023, apparent rodent excreta pellets with a black, shiny, and soft appearance, too numerous to count, between ingredient bags and directly below a storage rack used to store bulk dry ingredients.\n\nOn January 31, 2023, apparent insect activity on a glue trap next to a (b)(4) with an approximately one-inch gap.\n\nOn February 8, 2023, multiple apparent dead insects attached to two glue traps, adjacent to the (b)(4) oven. In addition, a section of the glue trap was torn, which you stated was due to a mouse that chewed through the glue trap to escape when it was caught on the trap.\n\nOn February 13, 2023, apparent rodent excreta pellets with a black, dull, and hard appearance, too numerous to count, inside an enclosed shelf under the (b)(4) behind boxes containing icing piping bags and on a sheet pan used to store RTE brownies prior to slicing.\n\nThis is a repeat observation from FDA’s 2020 inspection, as apparent rodent excrement was observed on and around an in-use caramel container used as a topping on RTE desserts, and on a shelf directly below where plates for the slicing machine are stored.\n\nYour March 7, 2023 response stated that you disposed of glue traps with captured pests, placed new glue traps, removed rodent excreta pellets, cleaned and sanitized areas where rodent excreta pellets were found, added cleaning tasks to your (b)(4) sanitization schedule, and will schedule garage door maintenance. However, your response does not show that the corrective actions are being implemented on a continual basis, and that they are effectively excluding pests from your facility. Additionally, you did not provide evidence of the scheduled garage maintenance, such as a maintenance request or work order.\n\nWe note that your most recent response includes corrective actions that you previously submitted to FDA on March 8, 2020, in response to FDA’s 2020 inspectional findings. As corrective action to the rodent excrement, your 2020 response stated that you cleaned and sanitized areas exposed to rodent excrement and placed new glue traps. However, during FDA’s most recent inspection, the investigators observed similar conditions, demonstrating that your corrective actions were inadequate and pest activity continues to persist in your facility. Additionally, during the most recent inspection, the FDA investigator discussed with you using a professional pest control service, you stated that you would contact a professional pest control company to inquire about servicing your facility; however, your response did not mention acquiring professional pest control services.\n\nFailure to Register Food Facility:\n\nIn addition, FDA has determined that your facility at 5285 Crookshank Road, Cincinnati, Ohio 45238 is subject to the food facility registration requirement in section 415 of the Act [21 U.S.C. § 350d], and our implementing regulation at 21 CFR Part 1, Subpart H. Section § 415(a)(3) of the Act requires facilities that are required to register with FDA to renew their registrations every other year during the period beginning on October 1 and ending on December 31 of each even-numbered year. (b)(3). Failure to register a facility as required is a prohibited act under section 301(dd) of the Act [21 U.S.C. § 331(dd)].\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\nWe request that the owner, operator, or agent in charge of this facility, or an individual authorized by this facility’s owner, operator, or agent in charge, register the facility with FDA within 30 working days of date of this letter. Food facility registration guidance is available online at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions. Registration may be accomplished online at http:\u002F\u002Fwww.access.fda.gov. You must submit your registration or registration renewal to FDA electronically, unless FDA has granted you a waiver under 21 CFR 1.245 (21 CFR 1.231(a)(4)).\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may also reach Christopher Dedeaux at 504-846-6122 or if you have any questions regarding this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Gary’s Cheesecakes & Fine Desserts","garys-cheesecakes-fine-desserts-654471-04282023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgarys-cheesecakes-fine-desserts-654471-04282023","2026-10-26T08:08:44.691995+00:00","Warning Letter","Closed Out","2023-05-16","654471","Food & Beverages","2023-11-17","Division of Human and Animal Food Operations East V","Gary W. Haas","2026-08-20T01:06:53.772+00:00","United Parcel Service","2023-04-28",{"id":36,"raw":37,"subject":42,"body_html":43,"body_text":44,"firm_name":45,"letter_id":46,"created_at":47,"fei_number":21,"letter_url":48,"updated_at":49,"action_type":24,"case_status":50,"posted_date":51,"marcs_cms_no":52,"product_type":53,"closeout_date":21,"issuing_office":41,"recipient_name":54,"body_fetched_at":55,"delivery_method":56,"recipient_title":21,"reference_number":21,"action_taken_date":51,"medical_device_id":21,"response_letter_date":21},2575,[38,39,40,41,42,13,13,13],"\u003Ctime datetime=\"2022-07-14T16:00:00Z\">07\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-14T04:00:00Z\">07\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsecret-city-vapor-636054-07142022\">Secret City Vapor\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tarl Kendall\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Secret City Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1966 Oak Ridge Turnkpike\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oak Ridge\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>37830\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tarl@secretcityvapors.com\"> tarl@secretcityvapors.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 14, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kendall:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Secret City Vapors LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Secret City Vapor POM POM 6MG 120ML e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 700 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003414, on September 8, 2020. However, FDA issued a negative action for STN PM0003414 in the form of a Refuse To Accept determination on June 29, 2021, which covers 581 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003414 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200583, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTarl Kendall\n\nRecipient Title\n\nOwner\n\nSecret City Vapor\n\n1966 Oak Ridge Turnkpike\n\nOak Ridge, TN 37830\n\nUnited States\n\ntarl@secretcityvapors.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJuly 14, 2022\n\nWARNING LETTER\n\nDear Mr. Kendall:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Secret City Vapors LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Secret City Vapor POM POM 6MG 120ML e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 700 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003414, on September 8, 2020. However, FDA issued a negative action for STN PM0003414 in the form of a Refuse To Accept determination on June 29, 2021, which covers 581 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003414 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200583, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Secret City Vapor","secret-city-vapor-636054-07142022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsecret-city-vapor-636054-07142022","2026-10-26T08:09:55.04674+00:00","Issued","2022-07-14","636054","Tobacco","Tarl Kendall","2026-08-20T01:46:02.854+00:00","VIA UPS and Electronic Mail",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":21,"letter_url":70,"updated_at":71,"action_type":24,"case_status":50,"posted_date":72,"marcs_cms_no":73,"product_type":74,"closeout_date":21,"issuing_office":63,"recipient_name":75,"body_fetched_at":76,"delivery_method":21,"recipient_title":21,"reference_number":21,"action_taken_date":77,"medical_device_id":21,"response_letter_date":21},3211,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2021-08-11T14:00:00Z\">08\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-10T04:00:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsecret-islands-616344-08102021\">Secret of the Islands\u003C\u002Fa>","Center for Drug Evaluation and Research","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joanne Bolles\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Secret of the Islands\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5326 Bush River Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Columbia\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29212\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:privacy@secretoftheislands.com\"> privacy@secretoftheislands.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>WARNING LETTER\u003C\u002Fp>\n\n\u003Cp>Date:&nbsp; August 10, 2021\u003C\u002Fp>\n\n\u003Cp>TO:&nbsp;&nbsp;&nbsp; privacy@secretoftheislands.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joanne Bolles, President\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Secret of The Islands, Inc.\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5326 Bush River Rd.\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Columbia, SC 29212\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nRE:&nbsp;&nbsp; Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsecretoftheislands.com on July 26, 2021. We also reviewed your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002FSecretoftheIslands, where you direct consumers to your website, https:\u002F\u002Fsecretoftheislands.com, to purchase your products. The FDA has observed that your website offers various salt scrub products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Ca id=\"footnoteref1_sh53lnk\" href=\"#footnote1_sh53lnk\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.&nbsp;\u003Ca id=\"footnoteref2_4b1a5ih\" href=\"#footnote2_4b1a5ih\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.&nbsp;\u003Ca id=\"footnoteref3_yqfc1x5\" href=\"#footnote3_yqfc1x5\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Examples of claims on your websites, that establish the intended use of your salt scrub products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“The world’s first &amp; only doctor approved anti-bacterial &amp; anti-viral salt scrub that kills\u002Fdeactivates the Coronavirus” [From your webpage https:\u002F\u002Fsecretoftheislands.com and from a similar March 19, 2021 posting on your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002FSecretoftheIslands\u002F]\u003Cbr>\n•&nbsp;“Due to the Coronavirus, there is a shortage of 12 oz jars. . .” [From your webpage https:\u002F\u002Fsecretoftheislands.com]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations.&nbsp; It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. Within 48 hours, please send an email to \u003Ca href=\"mailto:COVID-19-Task-Force-CDER@fda.hhs.gov\">COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fa> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Ca href=\"mailto:COVID-19-Task-Force-CDER@fda.hhs.gov\">COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_sh53lnk\">\u003Ca href=\"#footnoteref1_sh53lnk\">1\u003C\u002Fa>As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_4b1a5ih\">\u003Ca href=\"#footnoteref2_4b1a5ih\">2\u003C\u002Fa>Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_yqfc1x5\">\u003Ca href=\"#footnoteref3_yqfc1x5\">3\u003C\u002Fa>Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19)\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJoanne Bolles\n\nRecipient Title\n\nPresident\n\nSecret of the Islands\n\n5326 Bush River Rd.\n\nColumbia, SC 29212\n\nUnited States\n\nprivacy@secretoftheislands.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWARNING LETTER\n\nDate: August 10, 2021\n\nTO: privacy@secretoftheislands.com Joanne Bolles, President\n\nSecret of The Islands, Inc.\n\n5326 Bush River Rd.\n\nColumbia, SC 29212\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsecretoftheislands.com on July 26, 2021. We also reviewed your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002FSecretoftheIslands, where you direct consumers to your website, https:\u002F\u002Fsecretoftheislands.com, to purchase your products. The FDA has observed that your website offers various salt scrub products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. 2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. 3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nExamples of claims on your websites, that establish the intended use of your salt scrub products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n• “The world’s first & only doctor approved anti-bacterial & anti-viral salt scrub that kills\u002Fdeactivates the Coronavirus” [From your webpage https:\u002F\u002Fsecretoftheislands.com and from a similar March 19, 2021 posting on your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002FSecretoftheIslands\u002F]\n\n• “Due to the Coronavirus, there is a shortage of 12 oz jars. . .” [From your webpage https:\u002F\u002Fsecretoftheislands.com]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n1As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19)","Secret of the Islands","secret-islands-616344-08102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsecret-islands-616344-08102021","2026-10-26T08:09:55.093686+00:00","2021-08-11","616344","Drugs","Joanne Bolles","2026-08-20T02:42:11.467+00:00","2021-08-10",{"id":79,"raw":80,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":69,"fei_number":21,"letter_url":90,"updated_at":91,"action_type":24,"case_status":50,"posted_date":92,"marcs_cms_no":93,"product_type":94,"closeout_date":21,"issuing_office":84,"recipient_name":95,"body_fetched_at":96,"delivery_method":21,"recipient_title":21,"reference_number":21,"action_taken_date":97,"medical_device_id":21,"response_letter_date":21},3358,[81,82,83,84,85,13,13,13],"\u003Ctime datetime=\"2021-05-12T13:20:00Z\">05\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-04T04:00:00Z\">05\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaltimore-beauty-security-square-mall-614182-05042021\">Baltimore Beauty Security Square Mall\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yoo Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Baltimore Beauty Security Square Mall\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6901 Security Square Blvd. #343\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baltimore\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21244\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mrbulgogi01@gmail.com\"> mrbulgogi01@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: May 4, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has observed that your business offers for sale the GenBody COVID-19 Ag test (hereinafter “GenBody antigen test”) and the GenBody COVID-19 IgM\u002FIgG test (both hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Test Kits are offered for sale directly to consumers in the United States without marketing approval, clearance, or authorization from FDA.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medicaldevices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological\u003Cbr>\nHealth\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> One of the “COVID-19 Test Kits” you are offering for sale appears to be the GenBody COVID-19 IgM\u002FIgG test manufactured by GenBody, Inc. The GenBody COVID-19 IgM\u002FIgG test manufactured by GenBody, Inc., is currently listed on FDA’s “removed” serology test list, found on the FDA’s Removal Lists of Tests that Should No Longer Be Used and\u002For Distributed for COVID-19: FAQs on Testing for SARS-CoV-2 webpage at&nbsp;https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fremoval-lists-tests-should-no-longer-be-used-andor-distributed-covid-19-faqs-testing-sars-cov-2. The “removed” serology test list includes serology tests for which an EUA request was not submitted within a reasonable period of time, serology tests where significant problems are identified that cannot be or have not been addressed in a timely manner, and serology tests for which notification was voluntarily withdrawn by the commercial manufacturer. Tests on the “removed” serology test list should not be distributed in the United States unless and until an EUA is issued for the test or the test receives marketing approval or clearance from FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nYoo Kim\n\nBaltimore Beauty Security Square Mall\n\n6901 Security Square Blvd. #343\n\nBaltimore, MD 21244\n\nUnited States\n\nmrbulgogi01@gmail.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: May 4, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThe United States Food and Drug Administration (FDA) has observed that your business offers for sale the GenBody COVID-19 Ag test (hereinafter “GenBody antigen test”) and the GenBody COVID-19 IgM\u002FIgG test (both hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Test Kits are offered for sale directly to consumers in the United States without marketing approval, clearance, or authorization from FDA.2 Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medicaldevices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological\n\nHealth\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 One of the “COVID-19 Test Kits” you are offering for sale appears to be the GenBody COVID-19 IgM\u002FIgG test manufactured by GenBody, Inc. The GenBody COVID-19 IgM\u002FIgG test manufactured by GenBody, Inc., is currently listed on FDA’s “removed” serology test list, found on the FDA’s Removal Lists of Tests that Should No Longer Be Used and\u002For Distributed for COVID-19: FAQs on Testing for SARS-CoV-2 webpage at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fremoval-lists-tests-should-no-longer-be-used-andor-distributed-covid-19-faqs-testing-sars-cov-2. The “removed” serology test list includes serology tests for which an EUA request was not submitted within a reasonable period of time, serology tests where significant problems are identified that cannot be or have not been addressed in a timely manner, and serology tests for which notification was voluntarily withdrawn by the commercial manufacturer. Tests on the “removed” serology test list should not be distributed in the United States unless and until an EUA is issued for the test or the test receives marketing approval or clearance from FDA.\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx).\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Baltimore Beauty Security Square Mall","baltimore-beauty-security-square-mall-614182-05042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaltimore-beauty-security-square-mall-614182-05042021","2026-10-26T08:08:01.255035+00:00","2021-05-12","614182","Medical Devices","Yoo Kim","2026-08-20T03:08:30.527+00:00","2021-05-04",{"id":99,"raw":100,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":20,"fei_number":21,"letter_url":110,"updated_at":111,"action_type":24,"case_status":50,"posted_date":112,"marcs_cms_no":113,"product_type":74,"closeout_date":21,"issuing_office":104,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":21,"reference_number":21,"action_taken_date":117,"medical_device_id":21,"response_letter_date":21},2252,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2023-01-17T14:20:00Z\">01\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhis-enterprise-inc-dba-adams-secret-usa-llc-646494-01102023\">HIS Enterprise Inc dba Adam’s Secret USA, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kwang Pyo Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>HIS Enterprise Inc dba Adam’s Secret USA, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>460 Bergen Blvd., #222\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Palisades Park\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07650\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:adamssecretusa@gmail.com\"> adamssecretusa@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@adamssecret.com\"> info@adamssecret.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 10, 2023\u003C\u002Fp>\n\n\u003Cp>PO Box 281\u003Cbr>\nPalisades Park, NJ 07650\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 646494\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Lee:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.adamssecret.com, in May 2022 and again in December 2022, where you take orders for “Adam’s Secret Extra Strength 3000 Platinum,” “Adam’s Secret Extra Strength Blue,” “Adam’s Secret Extra Strength Purple,” “Adam's Secret Extra Strength Amazing Black,” “Adam’s Secret Extra Strength 2000,” (hereinafter referred to as your “Adam’s Secret” products) and “Dr. Reade Slim Sense.” We also reviewed your social media websites at www.instagram.com\u002Fadamssecretus and www.facebook.com\u002FAdamsSecretUSA, where you direct consumers to your website, www.adamssecret.com, to purchase your products. In addition, FDA has obtained samples and labeling of your Adam’s Secret and “Dr. Reade Slim Sense” products. As described below, these products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your Adam’s Secret and “Dr. Reade Slim Sense” products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. 352 and sold in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>FDA confirmed through laboratory analysis that samples of your Adam’s Secret and “Dr. Slim Sense” products contain undeclared pharmaceutical ingredients.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Specifically, samples of your “Adam’s Secret Extra Strength 3000 Platinum,” “Adam’s Secret Extra Strength Blue,” and “Adam's Secret Extra Strength Amazing Black,” products contain tadalafil, a phosphodiesterase type-5 (PDE-5) inhibitor. In addition, samples of your “Adam’s Secret Extra Strength Purple” and “Adam’s Secret Extra Strength 2000” products contain tadalafil and sildenafil. Tadalafil is a phosphodiesterase type-5 (PDE-5) inhibitor and the active ingredient in the FDA-approved prescription drug Cialis used to treat erectile dysfunction (ED). Sildenafil is a PDE-5 inhibitor and the active ingredient in the FDA-approved prescription drug Viagra also used to treat ED. These undeclared ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease, often take nitrates. Additionally, FDA confirmed through laboratory analysis that a sample of your “Dr. Reade Slim Sense” product contains lorcaserin, a controlled substance and the active ingredient in the withdrawn prescription drug Belviq, formerly used for chronic weight management in some overweight or obese adults. Lorcaserin may cause psychiatric disturbances and impairments in attention or memory. Further, this hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events. Belviq was withdrawn from the market on September 2020 after FDA requested that the manufacturer voluntarily withdraw the drug because of a safety clinical trial that showed an increased occurrence of cancer.\u003C\u002Fp>\n\n\u003Cp>Information on the labels and\u002For labeling of your Adam’s Secret and “Dr. Reade Slim Sense” products demonstrate that they are marketed as dietary supplements. However, under section 201(ff)(3)(B)(i) of the FD&amp;C Act, 21 U.S.C. 321(ff)(3)(B)(i), a dietary supplement may not include an article that is approved as a new drug under section 505 of the FD&amp;C Act unless that article was marketed as a dietary supplement or food before its approval as a drug. FDA approved Cialis (containing tadalafil as the active ingredient) as a new drug on November 21, 2003, and approved Viagra (containing sildenafil as the active ingredient) as a new drug on March 27, 1998. Given that tadalafil and sildenafil were not marketed as dietary supplements or as food before Cialis and Viagra were approved, your Adam’s Secret products are excluded from the definition of dietary supplement under section 201(ff)(3)(B)(i) of the FD&amp;C Act, 21 U.S.C. 321(ff)(3)(B)(i).\u003C\u002Fp>\n\n\u003Cp>Similarly, “Dr. Reade Slim Sense,” which contains lorcaserin, is also excluded from the definition of a dietary supplement. According to section 201(ff)(3)(B)(ii) of the FD&amp;C Act, 21 U.S.C. 321 (ff)(3)(B)(ii), the definition of a dietary supplement does not include an article authorized for investigation as a new drug for which substantial clinical investigations have been instituted and made public unless the article was marketed as a dietary supplement or food before its authorization for investigation as a new drug. Lorcaserin has been authorized for investigation as a new drug under an investigational new drug (IND) application. When Belviq was approved for marketing as a new drug in the United States, the existence of substantial completed clinical investigations of lorcaserin became public. Based on the information available to FDA, lorcaserin was not marketed as a dietary supplement or as a food before it was authorized for investigation as a new drug. Therefore, “Dr. Reade Slim Sense,” which contains lorcaserin, is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(ii) of the FD&amp;C Act, 21 U.S.C. 321 (ff)(3)(B)(ii).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Adam’s Secret and your “Dr. Reade Slim Sense” products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your website and social media websites that establish the intended use of your Adam’s Secret and “Dr. Reade Slim Sense” products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adam’s Secret Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>From your product page for your Adam’s Secret products, on your website www.adamssecret.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Take 45~60 minutes before sexual activity to produce harder, bigger and longer erections. One capsule will be effective for up to 4 days and always under your control. Get hard when you want. This pill is all you need to enhance your blood flow and testosterone level whenever there’s sexual activity.”\u003C\u002Fli>\n\t\u003Cli>“Many customers consume this enhancement pill on a weekly basis to revive their sexual confidence, as well as erections and stamina. Adam’s Secret can also help men with erectile dysfunction, premature ejaculation, and weak prostate.”\u003C\u002Fli>\n\t\u003Cli>Your Adam’s Secret products include “Tags: Erectile Dysfunction” under their product description.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.adamssecret.com\u002Fpages\u002Fabout:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Adams Secret is a holistic alternative to big pharma and is comparable to popular prescription drugs.”\u003C\u002Fli>\n\t\u003Cli>Under “Adams Secret 100% Natural Ingredients”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Native to the Peruvian Andes mountain range, Maca is known to help enhance libido, increase sperm count, plus improve mood and energy.”\u003Cbr>\n&nbsp; &nbsp; o “Ginkgo biloba is a tree native to China. The extract is made from the tree’s fan-shaped leaves. Its purpose in their formula is to increase blood flow and circulation.”\u003Cbr>\n&nbsp; &nbsp; o “Saw Palmetto . . . In Adams Secret, it is a great natural ingredient to help naturally boost testosterone.”\u003Cbr>\n&nbsp; &nbsp; o “Epimedium Sagitatum . . . It is sometimes referred to as a ‘natural viagra’ because it similarly increases blood flow to the penis, just like Viagra, without the potential side effects.”\u003Cbr>\n&nbsp; &nbsp; o “Stinging nettle is most commonly used for diabetes and osteoarthritis. It is also sometimes used for urinary tract infections (UTIs), kidney stones, enlarged prostate, hay fever, and other conditions.”\u003Cbr>\n&nbsp; &nbsp; o “Cnidium is most commonly used for increasing sexual performance and sex drive, erectile dysfunction (ED).”\u003Cbr>\n&nbsp; &nbsp; o “Tongkat Ali . . . It’s often used to treat a variety of ailments, including fevers, erectile dysfunction, and bacterial infections.”\u003Cbr>\n&nbsp; &nbsp; o “Forskolin works on muscles in the heart and in the walls of the blood vessels. It produces a more powerful heartbeat and widening of the blood vessels, which lowers blood pressure.”\u003C\u002Fp>\n\n\u003Cp>From your website www.adamssecret.com, clicking on “Read More” directs to an article titled “Just Take It Adams Secret” at www.inlovemag.com\u002Fjust-take-it\u002F, which includes many of the claims listed under the previous sub bullets, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Native to the Peruvian Andes mountain range, Maca is known to help enhance libido, increase sperm count, plus improve mood and energy.”\u003C\u002Fli>\n\t\u003Cli>“Ginkgo biloba is a tree native to China. The extract is made from the tree’s fan-shaped leaves. Its purpose in their formula is to increase blood flow and circulation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your social media pages, at www.instagram.com\u002Fadamssecretus and www.facebook.com\u002FAdamsSecretUSA, you posted the following on November 15, 2022:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A post that links to your website www.adamssecret.com and includes the following hashtags: “#adamssecret,” “#erectiledysfunction,” “#erectiledysfunctiontreatment”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>“Dr. Reade Slim Sense”\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>From your website www.adamssecret.com\u002Fproducts\u002Fslim-sense-10-capsules:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Clinically Proven Fat Binder 10 Day Plan (10 Capsules: Effective Weight Loss of 8-12 lbs\u002Fmonth Boosts Energy &amp; Supports Metabolism”\u003C\u002Fli>\n\t\u003Cli>An image of the product’s label on your website states: “Clinically proven fat burner for healthy and safe weight loss.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Adam’s Secret and “Dr. Reade Slim Sense” products are not generally recognized as safe and effective for their above referenced uses and, therefore, they are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There is no FDA-approved application in effect for your Adam’s Secret or “Dr. Reade Slim Sense” products. Introduction or delivery for introduction of these product into interstate commerce without an approved application violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Adam’s Secret and “Dr. Reade Slim Sense” products are also misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fail to bear adequate directions for use. “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). All PDE-5 inhibitors which have been approved for marketing by FDA are limited by an approved new drug application to use under the supervision of a practitioner licensed by law to administer such drugs. Your Adam’s Secret products, which contain undeclared sildenafil and\u002For tadalafil, and your “Dr. Reade Slim Sense” product, which contains undeclared lorcaserin, are prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. Prescription drugs can be used safely only at the direction, and under the supervision, of a licensed practitioner. Therefore, it is impossible to write “adequate directions for use” for prescription drugs, including your Adam’s Secret and “Dr. Reade Slim Sense” products. Your Adam’s Secret and “Dr. Reade Slim Sense” products are not exempt from the requirements that their labeling bear adequate directions for use by a layperson, 21 CFR 201.100(c)(2) and 201.115, because there is no FDA approved application in effect for these products. For these reasons, your Adam’s Secret and “Dr. Reade Slim Sense” products are misbranded under section 502(f)(1) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, your Adam’s Secret and “Dr. Reade Slim Sense” products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that, in determining whether an article's labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your Adam’s Secret and “Dr. Reade Slim Sense” products do not declare that the products contain a PDE-5 inhibitor or lorcacerin. The use of PDE-5 inhibitors can be associated with significant safety issues and the risk of serious adverse events. The undeclared PDE-5 inhibitors in your Adam’s Secret products may pose serious health risks because consumers with underlying medical issues may take the products without knowing that they can cause serious harm or interact in dangerous ways with other drugs they may be taking. For example, PDE-5 inhibitors may interact with nitrates found in some prescription drugs (such as nitroglycerin) and can lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, or heart disease often take nitrates. The presence of undeclared lorcaserin in your “Dr. Reade Slim Sense” product may cause psychiatric disturbances and impairments in attention or memory. Further, this hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events. The failure to disclose these ingredients in the products’ labeling renders your Adam’s Secret and “Dr. Reade Slim Sense” products misbranded under section 502(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The undeclared active pharmaceutical ingredients in your products also cause these products to be misbranded under section 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2), because their labeling lacks adequate warnings for the protection of users. As previously noted, there is potential for adverse events associated with the use of PDE-5 inhibitors and\u002For lorcaserin. Consumers who use your Adam’s Secret and\u002For your “Dr. Reade Slim Sense” products would be unaware of the presence of the undeclared drug ingredients and placed at risk for their associated adverse events.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA has issued warnings to consumers not to use your Adam’s Secret and “Dr. Reade Slim Sense” products. See: \u003Cem>Public Notification: Adam’s Secret Extra Strength Amazing Black contains hidden drug ingredient\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient\u003C\u002Fa>, \u003Cem>Public Notification: Dr. Reade Slim Sense contains hidden drug ingredient\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-dr-reade-slim-sense-contains-hidden-drug-ingredient\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-dr-reade-slim-sense-contains-hidden-drug-ingredient\u003C\u002Fa>, \u003Cem>Public Notification: Adam’s Secret Extra Strength 3000 Platinum (White Packaging) contains hidden drug ingredient\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-3000-platinum-white-packaging-contains-hidden-drug\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-3000-platinum-white-packaging-contains-hidden-drug\u003C\u002Fa>,\u003Cem> Public Notification: Adam’s Secret Extra Strength Blue contains hidden drug ingredient\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-blue-contains-hidden-drug-ingredient\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-blue-contains-hidden-drug-ingredient\u003C\u002Fa>, \u003Cem>Public Notification: Adam’s Secret Extra Strength 2000 contains hidden drug ingredients\u003C\u002Fem>&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-2000-contains-hidden-drug-ingredients#:~:text=FDA%20laboratory%20analysis%20confirmed%20that,a%20licensed%20health%20care%20professional\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-2000-contains-hidden-drug-ingredients#:~:text=FDA%20laboratory%20analysis%20confirmed%20that,a%20licensed%20health%20care%20professional\u003C\u002Fa>. and \u003Cem>Public Notification: Adam’s Secret Extra Strength Purple contains hidden drug ingredients\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-purple-contains-hidden-drug-ingredients\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-purple-contains-hidden-drug-ingredients\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKwang Pyo Lee\n\nHIS Enterprise Inc dba Adam’s Secret USA, LLC\n\n460 Bergen Blvd., #222\n\nPalisades Park, NJ 07650\n\nUnited States\n\nadamssecretusa@gmail.com\n\ninfo@adamssecret.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nJanuary 10, 2023\n\nPO Box 281\n\nPalisades Park, NJ 07650\n\nRE: 646494\n\nDear Mr. Lee:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.adamssecret.com, in May 2022 and again in December 2022, where you take orders for “Adam’s Secret Extra Strength 3000 Platinum,” “Adam’s Secret Extra Strength Blue,” “Adam’s Secret Extra Strength Purple,” “Adam's Secret Extra Strength Amazing Black,” “Adam’s Secret Extra Strength 2000,” (hereinafter referred to as your “Adam’s Secret” products) and “Dr. Reade Slim Sense.” We also reviewed your social media websites at www.instagram.com\u002Fadamssecretus and www.facebook.com\u002FAdamsSecretUSA, where you direct consumers to your website, www.adamssecret.com, to purchase your products. In addition, FDA has obtained samples and labeling of your Adam’s Secret and “Dr. Reade Slim Sense” products. As described below, these products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your Adam’s Secret and “Dr. Reade Slim Sense” products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352 and sold in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nFDA confirmed through laboratory analysis that samples of your Adam’s Secret and “Dr. Slim Sense” products contain undeclared pharmaceutical ingredients.1 Specifically, samples of your “Adam’s Secret Extra Strength 3000 Platinum,” “Adam’s Secret Extra Strength Blue,” and “Adam's Secret Extra Strength Amazing Black,” products contain tadalafil, a phosphodiesterase type-5 (PDE-5) inhibitor. In addition, samples of your “Adam’s Secret Extra Strength Purple” and “Adam’s Secret Extra Strength 2000” products contain tadalafil and sildenafil. Tadalafil is a phosphodiesterase type-5 (PDE-5) inhibitor and the active ingredient in the FDA-approved prescription drug Cialis used to treat erectile dysfunction (ED). Sildenafil is a PDE-5 inhibitor and the active ingredient in the FDA-approved prescription drug Viagra also used to treat ED. These undeclared ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease, often take nitrates. Additionally, FDA confirmed through laboratory analysis that a sample of your “Dr. Reade Slim Sense” product contains lorcaserin, a controlled substance and the active ingredient in the withdrawn prescription drug Belviq, formerly used for chronic weight management in some overweight or obese adults. Lorcaserin may cause psychiatric disturbances and impairments in attention or memory. Further, this hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events. Belviq was withdrawn from the market on September 2020 after FDA requested that the manufacturer voluntarily withdraw the drug because of a safety clinical trial that showed an increased occurrence of cancer.\n\nInformation on the labels and\u002For labeling of your Adam’s Secret and “Dr. Reade Slim Sense” products demonstrate that they are marketed as dietary supplements. However, under section 201(ff)(3)(B)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i), a dietary supplement may not include an article that is approved as a new drug under section 505 of the FD&C Act unless that article was marketed as a dietary supplement or food before its approval as a drug. FDA approved Cialis (containing tadalafil as the active ingredient) as a new drug on November 21, 2003, and approved Viagra (containing sildenafil as the active ingredient) as a new drug on March 27, 1998. Given that tadalafil and sildenafil were not marketed as dietary supplements or as food before Cialis and Viagra were approved, your Adam’s Secret products are excluded from the definition of dietary supplement under section 201(ff)(3)(B)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i).\n\nSimilarly, “Dr. Reade Slim Sense,” which contains lorcaserin, is also excluded from the definition of a dietary supplement. According to section 201(ff)(3)(B)(ii) of the FD&C Act, 21 U.S.C. 321 (ff)(3)(B)(ii), the definition of a dietary supplement does not include an article authorized for investigation as a new drug for which substantial clinical investigations have been instituted and made public unless the article was marketed as a dietary supplement or food before its authorization for investigation as a new drug. Lorcaserin has been authorized for investigation as a new drug under an investigational new drug (IND) application. When Belviq was approved for marketing as a new drug in the United States, the existence of substantial completed clinical investigations of lorcaserin became public. Based on the information available to FDA, lorcaserin was not marketed as a dietary supplement or as a food before it was authorized for investigation as a new drug. Therefore, “Dr. Reade Slim Sense,” which contains lorcaserin, is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(ii) of the FD&C Act, 21 U.S.C. 321 (ff)(3)(B)(ii).\n\nUnapproved New Drugs\n\nYour Adam’s Secret and your “Dr. Reade Slim Sense” products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your website and social media websites that establish the intended use of your Adam’s Secret and “Dr. Reade Slim Sense” products as drugs include, but are not limited to, the following:\n\nAdam’s Secret Products\n\nFrom your product page for your Adam’s Secret products, on your website www.adamssecret.com:\n\n“Take 45~60 minutes before sexual activity to produce harder, bigger and longer erections. One capsule will be effective for up to 4 days and always under your control. Get hard when you want. This pill is all you need to enhance your blood flow and testosterone level whenever there’s sexual activity.”\n\n“Many customers consume this enhancement pill on a weekly basis to revive their sexual confidence, as well as erections and stamina. Adam’s Secret can also help men with erectile dysfunction, premature ejaculation, and weak prostate.”\n\nYour Adam’s Secret products include “Tags: Erectile Dysfunction” under their product description.\n\nFrom your website www.adamssecret.com\u002Fpages\u002Fabout:\n\n“Adams Secret is a holistic alternative to big pharma and is comparable to popular prescription drugs.”\n\nUnder “Adams Secret 100% Natural Ingredients”\n\no “Native to the Peruvian Andes mountain range, Maca is known to help enhance libido, increase sperm count, plus improve mood and energy.”\n\no “Ginkgo biloba is a tree native to China. The extract is made from the tree’s fan-shaped leaves. Its purpose in their formula is to increase blood flow and circulation.”\n\no “Saw Palmetto . . . In Adams Secret, it is a great natural ingredient to help naturally boost testosterone.”\n\no “Epimedium Sagitatum . . . It is sometimes referred to as a ‘natural viagra’ because it similarly increases blood flow to the penis, just like Viagra, without the potential side effects.”\n\no “Stinging nettle is most commonly used for diabetes and osteoarthritis. It is also sometimes used for urinary tract infections (UTIs), kidney stones, enlarged prostate, hay fever, and other conditions.”\n\no “Cnidium is most commonly used for increasing sexual performance and sex drive, erectile dysfunction (ED).”\n\no “Tongkat Ali . . . It’s often used to treat a variety of ailments, including fevers, erectile dysfunction, and bacterial infections.”\n\no “Forskolin works on muscles in the heart and in the walls of the blood vessels. It produces a more powerful heartbeat and widening of the blood vessels, which lowers blood pressure.”\n\nFrom your website www.adamssecret.com, clicking on “Read More” directs to an article titled “Just Take It Adams Secret” at www.inlovemag.com\u002Fjust-take-it\u002F, which includes many of the claims listed under the previous sub bullets, including but not limited to:\n\n“Native to the Peruvian Andes mountain range, Maca is known to help enhance libido, increase sperm count, plus improve mood and energy.”\n\n“Ginkgo biloba is a tree native to China. The extract is made from the tree’s fan-shaped leaves. Its purpose in their formula is to increase blood flow and circulation.”\n\nFrom your social media pages, at www.instagram.com\u002Fadamssecretus and www.facebook.com\u002FAdamsSecretUSA, you posted the following on November 15, 2022:\n\nA post that links to your website www.adamssecret.com and includes the following hashtags: “#adamssecret,” “#erectiledysfunction,” “#erectiledysfunctiontreatment”\n\n“Dr. Reade Slim Sense”\n\nFrom your website www.adamssecret.com\u002Fproducts\u002Fslim-sense-10-capsules:\n\n“Clinically Proven Fat Binder 10 Day Plan (10 Capsules: Effective Weight Loss of 8-12 lbs\u002Fmonth Boosts Energy & Supports Metabolism”\n\nAn image of the product’s label on your website states: “Clinically proven fat burner for healthy and safe weight loss.”\n\nYour Adam’s Secret and “Dr. Reade Slim Sense” products are not generally recognized as safe and effective for their above referenced uses and, therefore, they are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There is no FDA-approved application in effect for your Adam’s Secret or “Dr. Reade Slim Sense” products. Introduction or delivery for introduction of these product into interstate commerce without an approved application violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\n\nMisbranded Drugs\n\nYour Adam’s Secret and “Dr. Reade Slim Sense” products are also misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fail to bear adequate directions for use. “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). All PDE-5 inhibitors which have been approved for marketing by FDA are limited by an approved new drug application to use under the supervision of a practitioner licensed by law to administer such drugs. Your Adam’s Secret products, which contain undeclared sildenafil and\u002For tadalafil, and your “Dr. Reade Slim Sense” product, which contains undeclared lorcaserin, are prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. Prescription drugs can be used safely only at the direction, and under the supervision, of a licensed practitioner. Therefore, it is impossible to write “adequate directions for use” for prescription drugs, including your Adam’s Secret and “Dr. Reade Slim Sense” products. Your Adam’s Secret and “Dr. Reade Slim Sense” products are not exempt from the requirements that their labeling bear adequate directions for use by a layperson, 21 CFR 201.100(c)(2) and 201.115, because there is no FDA approved application in effect for these products. For these reasons, your Adam’s Secret and “Dr. Reade Slim Sense” products are misbranded under section 502(f)(1) of the FD&C Act.\n\nAdditionally, your Adam’s Secret and “Dr. Reade Slim Sense” products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that, in determining whether an article's labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your Adam’s Secret and “Dr. Reade Slim Sense” products do not declare that the products contain a PDE-5 inhibitor or lorcacerin. The use of PDE-5 inhibitors can be associated with significant safety issues and the risk of serious adverse events. The undeclared PDE-5 inhibitors in your Adam’s Secret products may pose serious health risks because consumers with underlying medical issues may take the products without knowing that they can cause serious harm or interact in dangerous ways with other drugs they may be taking. For example, PDE-5 inhibitors may interact with nitrates found in some prescription drugs (such as nitroglycerin) and can lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, or heart disease often take nitrates. The presence of undeclared lorcaserin in your “Dr. Reade Slim Sense” product may cause psychiatric disturbances and impairments in attention or memory. Further, this hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events. The failure to disclose these ingredients in the products’ labeling renders your Adam’s Secret and “Dr. Reade Slim Sense” products misbranded under section 502(a) of the FD&C Act.\n\nThe undeclared active pharmaceutical ingredients in your products also cause these products to be misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2), because their labeling lacks adequate warnings for the protection of users. As previously noted, there is potential for adverse events associated with the use of PDE-5 inhibitors and\u002For lorcaserin. Consumers who use your Adam’s Secret and\u002For your “Dr. Reade Slim Sense” products would be unaware of the presence of the undeclared drug ingredients and placed at risk for their associated adverse events.\n\nThe introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n__________________________\n\n1 FDA has issued warnings to consumers not to use your Adam’s Secret and “Dr. Reade Slim Sense” products. See: Public Notification: Adam’s Secret Extra Strength Amazing Black contains hidden drug ingredient https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient, Public Notification: Dr. Reade Slim Sense contains hidden drug ingredient https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-dr-reade-slim-sense-contains-hidden-drug-ingredient, Public Notification: Adam’s Secret Extra Strength 3000 Platinum (White Packaging) contains hidden drug ingredient https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-3000-platinum-white-packaging-contains-hidden-drug, Public Notification: Adam’s Secret Extra Strength Blue contains hidden drug ingredient https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-blue-contains-hidden-drug-ingredient, Public Notification: Adam’s Secret Extra Strength 2000 contains hidden drug ingredients https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-2000-contains-hidden-drug-ingredients#:~:text=FDA%20laboratory%20analysis%20confirmed%20that,a%20licensed%20health%20care%20professional. and Public Notification: Adam’s Secret Extra Strength Purple contains hidden drug ingredients https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-adams-secret-extra-strength-purple-contains-hidden-drug-ingredients.","HIS Enterprise Inc dba Adam’s Secret USA, LLC","his-enterprise-inc-dba-adams-secret-usa-llc-646494-01102023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhis-enterprise-inc-dba-adams-secret-usa-llc-646494-01102023","2026-10-26T08:08:55.194829+00:00","2023-01-17","646494","Kwang Pyo Lee","2026-08-20T01:19:06.156+00:00","Via Email","2023-01-10",5,{"510k":120,"classification":121,"enforcement":122,"event":123,"event_backfill":124,"pma":125,"warning_letter":126},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]